Quintiles Announces New Brand Identity
Quintiles (Research Triangle Park, NC) has launched a new positioning and brand identity.
“The New Health is our description of the rapidly changing world of biopharma,” said Quintiles Chief Operating Officer John Ratliff in a company press release. “We define the New Health in a number of ways, both as a journey and as a destination. The term encapsulates the risks and opportunities biopharma faces in today’s changing economic and healthcare settings.”
Quintiles’ new positioning includes the introduction of a unified brand, a new visual system, an updated logo, and new company tag line (“Navigating the New Health"), all designed to communicate the company’s business approach and the transformative changes it is making within the biopharmaceutical industry.
The new brand identity is being launched behind an advertising campaign that communicates a patient-centric vision of change. The first wave of repositioning will be launched in online advertising and will be followed by a sustained trade and business media print campaign across the United States, Europe, and Japan.
For a video on the New Health, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
